S. Barnett

Examining inhibition of VEGFR and EGFR signaling in MMTV-neu transgenic mice with well-established tumors: an immunohistochemical and oncogenomic analysis of AZD2171, vandetanib and gefitinib treatment

A. Graham, H. Brown, S. Wedge, 2007 .

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

S. Barry, S. Wedge, J. Kendrew, 2005, Cancer research.

Thymidine salvage changes with differentiation in human keratinocytes in vitro.

H. Reuveni, P. M. Schwartz, S. Barnett, 1991, The Journal of investigative dermatology.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

J. Kendrew, J. Kemp, T. Stephens, 2005, Molecular Cancer Therapeutics.

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition

S. P. Guy, J. Kendrew, J. Kemp, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Methotrexate induces differentiation of human keratinocytes.

E. Atillasoy, P. M. Schwartz, L. Milstone, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Keratinocytes differentiate in response to inhibitors of deoxyribonucleotide synthesis.

P. M. Schwartz, L. Milstone, S. Barnett, 1995, Journal of dermatological science.

The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo

S. Wedge, J. Kendrew, P. Plé, 2004 .

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

A. Ryan, P. Elvin, Paul D. Smith, 2010 .